MedTrace Logo

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

NCT01101100 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2019-07-30

Study results available
· View outcomes & findings →

Summary

This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.

Conditions

Interventions

DRUG

AMG 827

210 mg SC or 140 mg SC

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States
  • Australia
  • Canada
  • Denmark
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01101100 on ClinicalTrials.gov